MSA Team Works Toward Publications

March 16, 2020

MSA has submitted three manuscripts in high impact journals that report the results of pre-clinical experiments evaluating the pharmacokinetics (nasal absorption), pharmacodynamics (efficacy), and safety in support of Bryn Pharma’s goal to bring a cost-effective intranasal delivery system for patients with anaphylaxis to market.

MSA authors include Principals Dr. Kenneth Dretchen Ph.D., Zack Mesa, and Michael Mesa, along with MSA associate Matt Robben Ph.D.

MSA News

MSA and COVID-19

Frederick, MD July 17, 2020 – MSA has decided to delay the full-time return to our Frederick offices indefinitely.  Unfortunately,…

Read More

Mesa Science Associates and Bryn Pharma Publish Final of Three Pre-Clinical Studies of a New Approach to Treating Anaphylaxis

The third in a series of studies measured cerebrospinal fluid epinephrine pharmacokinetics, nasal mucosa effects, plasma epinephrine pharmacokinetics, and cardiovascular…

Read More

Dr. Kenneth Dretchen PhD has been appointed as a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Discovery Research Award Committee.

May 22, 2020 This committee review grant applications for Pre-doctoral, Post-doctoral and Research Starter Grants dealing with innovative approaches that…

Read More